CUTISS has been nominated for the 2025 edition of the Prix Galien USA, which recognizes outstanding advances in medical and pharmaceutical innovation.
The nomination highlights our work in personalized regenerative medicine and the clinical development of denovoSkin™ as a novel skin tissue therapy for patients with severe skin injuries.
The awards ceremony in New York City brought together leading innovators from around the world.
